TY - JOUR AU - Abdul-Jalil, Asra’a A AU - Al-khafaji, Zahra M AU - Al-ouqaili, Mushtak T PY - 2018/08/07 Y2 - 2024/03/28 TI - INVESTIGATION OF ACCD3 GENE OF MYCOBACTERIUM TUBERCULOSIS IRAQI ISOLATES JF - Asian Journal of Pharmaceutical and Clinical Research JA - Asian J Pharm Clin Res VL - 11 IS - 8 SE - Original Article(s) DO - 10.22159/ajpcr.2018.v11i8.25269 UR - https://journals.innovareacademics.in/index.php/ajpcr/article/view/25269 SP - 208-211 AB - <p class="Pa7"><strong>Objective: </strong><em>Mycobacterium tuberculosis</em>, one of the deadliest human pathogens, causes several million new infections and about 2 million fatalities annually. The cell wall of <em>M. tuberculosis </em>is endowed with a highly impermeable, complex array of diverse lipids such as mycolic acids, which bestow the bacterium with not only virulence but also resistance to host immunity and antibiotics.</p><p class="Pa7"><strong>Methods: </strong>Mycobacterial lipid metabolism has thus emerged as an attractive target for the design and development of novel antimycobacterial therapeutics. The first committed step in the biosynthesis of mycolic acid is the carboxylation of acetyl-CoA to malonyl-CoA which is catalyzed by acetyl-coenzyme A carboxylase carboxyl transferase beta subunit (<em>accD3</em>), a primer pairs were designed computationally and used for the amplification of <em>accD3 </em>gene using conventional polymerase chain reaction (PCR) and sequencing the PCR product and analyze the results.</p><p class="Pa7"><strong>Results: </strong>Two sequences of the detection gene (<em>LprM </em>gene) and eight sequences of <em>accD3 </em>gene under study were deposited at NCBI – GenBank database with accession numbers (LC009881, LC009880.1, LC006979, LC008196, LC009412, LC009414, LC034168, LC038020, LC041163, and LC041368) and primer pairs deposited at Probe database/NCBI with accession number Pr032816836.</p><p><strong>Conclusion: </strong><em>AccD3 </em>gene is a good drug target in MDR <em>M. tuberculosis </em>strains.</p> ER -